Korro Bio Revenue

In the year 2024, Korro Bio had annual revenue of $2.27M. Korro Bio had revenue of $2.27M in the quarter ending December 31, 2024.

Revenue (ttm)

$2.27M

Revenue Growth

n/a

P/S Ratio

71.06

Revenue / Employee

$21,837

Employees

104

Market Cap

165.81M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.27M	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

KRRO News

25 days ago - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - GlobeNewsWire
5 weeks ago - Korro Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
6 weeks ago - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
2 months ago - Korro to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
5 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
5 months ago - Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
5 months ago - Korro to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
6 months ago - Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - GlobeNewsWire

More News